Well, the world has a new wonder drug for preventing HIV AIDS. The FDA approving Gilead's injectable just a few days ago. And joining us right now exclusively to talk about this is Gilead Sciences chairman and CEO Daniel OD.Dan, welcome. Thank you very much for coming here. I I know that this is something you've been working on for a very long time.I think we've been talking about it for over a year at this point, but this is Gilead's focus to try and bring new drugs and hopefully eventually eradicate this ...

行 业 及 产 业 海外消费服务 行 业 研 究 / 行 业 点 评 2025 年 06 月 20 日 供需优化，行业增长韧性十足——教育行业 2025 年下半年投资策略 看好 ——海外消费周报（20250613-20250619） 本期投资提示： ⚫ 海外教育：供需优化，行业增长韧性十足——教育行业 2025 年下半年投资策略 青年人群职业技能培训市场迎来需求井喷，行业景气度持续提升。我们预计随着大学毕业生 以及高考落榜生逐年增长，每年进入劳动力市场的青年人群数量将持续增长，使得技能培训 市场景气度持续提升。由于高中阶段（普通高中和中职）招生数量持续增加，毕业生人数持 续提升，而同期大学扩招缓慢，导致高考落榜生即高中毕业进入劳动力市场的人群数量持续 增加。同时大学毕业生持续增长，青年人群（16 至 24 岁）失业率普遍高于城镇居民失业 率，青年人群就业困难带动职业技能培训需求井喷。我们预计 25 年技能培训市场规模 800 亿元，且渗透率仍只有 5%，因此成长空间可期。 高教办学投入拐点显现，经营效率提升可期。随着职教改革持续深入，办学质量提升成行业 主基调。近三年民办高教在监管收紧办学质量时期纷纷增加办学 ...

政策动向 福建泉州落地医保基金即时结算 为切实提升医保基金结算效率，为有效缓解定点医药机构资金周转压力，近日，泉州市医保部门正式印 发《关于做好基本医保基金即时结算改革工作的通知》，推出基本医保基金即时结算模式。目前，泉州 市医保基金即时结算系统已成功上线运行。 6月19日，诺唯赞公告称拟通过集中竞价交易方式回购部分公司已发行的人民币普通股（A股），用于 实施股权激励或员工持股计划。回购股份金额为500万元（含）至1000万元（含），回购价格不超过30 元/股（含）。回购股份期限为自董事会审议通过本次回购股份方案之日起12个月内。 天康生物：控股子公司天康制药北交所上市辅导验收完成 根据相关报道，此次即时结算改革的核心在于建立"日拨付+月结算"的高效机制，通过"压缩结算周期 +增加拨付频次"的组合拳，构建资金拨付"双通道"。 药械审批 上海医药：普瑞巴林胶囊获泰国药监局批准 6月19日，上海医药公告称，下属上药泰国有限责任公司的普瑞巴林胶囊获得泰国食品药品监督管理局 颁发的药品注册证书，批准上市。该药品主要用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌 痛和脊髓损伤引起的神经性疼痛以及癫痫的辅助治疗。 吉 ...

Core Insights - Gilead Sciences, Inc. (GILD) received FDA approval for lenacapavir, branded as Yeztugo, a twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg [1][7][10] - Yeztugo is the first and only twice-yearly PrEP option available in the United States, representing a significant advancement in HIV prevention [1][10] - The approval was based on late-stage studies, PURPOSE 1 and PURPOSE 2, which demonstrated that ≥99.9% of participants who received Yeztugo remained HIV-negative [2][8] Company Performance - Year to date, GILD shares have increased by 18.6%, contrasting with a 4% decline in the industry [4] - The approval of Yeztugo enhances Gilead's HIV portfolio, especially as its other prevention drug, Truvada, faces generic competition [12] Competitive Landscape - Yeztugo's long-acting dosing aims to improve PrEP uptake by addressing adherence challenges and stigma associated with daily oral medications [7][10] - Gilead's flagship drug, Biktarvy, holds over 51% of the treatment market share in the United States, indicating strong market positioning [11] - The approval of Yeztugo is expected to catalyze uptake among historically underserved populations, providing a competitive advantage over daily oral pills [11][10] Regulatory and Market Developments - Yeztugo was granted Breakthrough Therapy Designation and has also received validation from the European Medicines Agency for marketing authorization [9] - The approval of long-acting injectable forms of PrEP, such as Yeztugo and ViiV Healthcare's Apretude, indicates a growing trend in HIV prevention strategies [13][14]

日发精机：意大利MCM公司申请破产 36氪获悉，日发精机发布公告，鉴于下属全资子公司Machining Centers Manufacturing S.p.A（简称"意大 利MCM公司"）因持续亏损，无法偿还到期债务且已出现流动性不足的情形，为维护公司及公司股东的 合法权益，公司董事会同意意大利MCM公司申请破产事项。意大利MCM公司的资产、业务均在境外， 与公司国内的业务、财务相对独立，申请破产不会对公司国内主营业务产生重大影响，不会对公司的持 续经营产生重大影响。 迪士尼中国携手上海美术电影制片厂推出动画宣传短片系列《疯狂动物城：动物城日与夜》 36氪获悉，迪士尼中国宣布与上海美术电影制片厂达成特别合作，邀请四位中国动画导演，以《疯狂动 物城》的故事为原点，巧妙运用偶（定格）、水墨、二维、剪纸等四种中国传统美术动画技法，推出动 画宣传短片系列《疯狂动物城：动物城日与夜》。四支完整短片预计将于2025年11月于全国各大社交及 视频平台发布，观众可免费观看。 B站推出动画短剧激励政策 大公司： 36氪获悉，B站发布了动画短剧的扶持政策"觉醒计划"，该计划面向UP主、MCN和动画短剧相关公 司，提供30%至10 ...

Core Viewpoint - Gilead's HIV-1 capsid inhibitor, Yeztugo (lenacapavir), has been approved by the FDA as a pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in adults and adolescents weighing at least 35 kg, marking a significant advancement in HIV prevention strategies [1][2]. Group 1: Drug Approval and Efficacy - Yeztugo is the first HIV prevention drug that requires administration only twice a year [2]. - In clinical trials (PURPOSE 1 and PURPOSE 2), over 99.9% of participants maintained an HIV-negative status, with PURPOSE 1 showing a 100% reduction in infection rates among cisgender women and PURPOSE 2 showing a 99.9% reduction among men who have sex with men, transgender men, transgender women, and non-binary individuals [2]. Group 2: Mechanism of Action - Lenacapavir works by binding directly to the HIV capsid protein subunits, regulating the stability and transport of the capsid, thereby preventing HIV from entering human cells and inhibiting multiple critical steps in the viral lifecycle [2][3]. - This multi-stage mechanism distinguishes lenacapavir from other approved antiretroviral drugs and shows no known cross-resistance with existing medications [2]. Group 3: Market Context and Future Implications - Prior to this approval, lenacapavir had not been authorized for pre-exposure prophylaxis in other countries, although it had been approved for treating multi-drug resistant HIV in the EU and the US [3]. - The introduction of a biannual dosing regimen could significantly improve adherence among high-risk populations who struggle with daily medication, potentially leading to a further decline in HIV prevalence if widely adopted [3].